本报道最初发表于Endpoints News。请点击这里查看原文
Eli Lilly is making its biggest acquisition in years, devoting part of its GLP-1 cash influx to buy Centessa Pharmaceuticals and its experimental medicines for sleep disorders and neurological conditions.
礼来(Eli Lilly)正进行近年来最大的一笔收购，动用其GLP-1带来的部分现金流入，收购森泰莎制药(Centessa Pharmaceuticals)及其用于睡眠障碍和神经系统疾病的实验性药物。
您已阅读9%（336字），剩余91%（3387字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。